Ejiri Junya, Inoue Nobutaka, Tsukube Takuro, Munezane Takashi, Hino Yutaka, Kobayashi Seiichi, Hirata Ken-ichi, Kawashima Seinosuke, Imajoh-Ohmi Shinobu, Hayashi Yoshitake, Yokozaki Hiroshi, Okita Yutaka, Yokoyama Mitsuhiro
Division of Cardiovascular and Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, chuo-ku, Kobe 650-0017, Japan.
Cardiovasc Res. 2003 Oct 1;59(4):988-96. doi: 10.1016/s0008-6363(03)00523-6.
The pathogenesis of thoracic aortic aneurysms (TAA) is still unclear. A recent investigation indicated that angiotensin II, a potent activator of NADH/NADPH oxidase, plays an important role in aneurysmal formation. We investigated the potential role of p22phox-based NADH/NADPH oxidase in the pathogenesis of TAA.
Human thoracic aneurysmal (n=40) and non-aneurysmal (control, n=39) aortic sections were examined, and the localization of p22phox, an essential component of the oxidase, and its expressional differences were investigated by immunohistochemistry and Western blot. In situ reactive oxygen species (ROS) generation was examined by the dihydroethidium method, and the impact of medical treatment on p22phox expression was investigated by multiple regression analysis.
In situ production of ROS and the expression of p22phox increased markedly in TAA throughout the wall, and Western blot confirmed the enhanced expression of p22phox. The expression was more intense in the regions where monocytes/macrophages accumulated. In these inflammatory regions, numerous chymase-positive mast cells and angiotensin converting enzyme-positive macrophages were present. Their localization closely overlapped the in situ activity of matrix metalloproteinase and the expression of p22phox. Multiple regression analysis revealed that medical treatment with statin and angiotensin II type 1 receptor blocker (ARB) suppressed p22phox expression in TAA.
Our findings indicate the role of p22phox-based NADH/NADPH oxidase and the local renin-angiotensin system in the pathogenesis of TAA. Statin and ARB might have inhibitory effects on the formation of aneurysms via the suppression of NADH/NADPH oxidase.
胸主动脉瘤(TAA)的发病机制仍不清楚。最近的一项研究表明,血管紧张素II作为烟酰胺腺嘌呤二核苷酸(NADH)/烟酰胺腺嘌呤二核苷酸磷酸(NADPH)氧化酶的强效激活剂,在动脉瘤形成中起重要作用。我们研究了基于p22吞噬细胞氧化还原辅酶Ⅱ氧化酶(p22phox)的NADH/NADPH氧化酶在TAA发病机制中的潜在作用。
检查人胸主动脉瘤(n = 40)和非动脉瘤(对照,n = 39)的主动脉切片,通过免疫组织化学和蛋白质印迹法研究氧化酶的重要组成部分p22phox的定位及其表达差异。采用二氢乙锭法检测原位活性氧(ROS)的产生,并通过多元回归分析研究药物治疗对p22phox表达的影响。
TAA整个管壁内ROS的原位产生及p22phox的表达均显著增加,蛋白质印迹法证实了p22phox表达增强。在单核细胞/巨噬细胞积聚的区域,表达更为强烈。在这些炎症区域,存在大量糜酶阳性肥大细胞和血管紧张素转换酶阳性巨噬细胞。它们的定位与基质金属蛋白酶的原位活性和p22phox的表达密切重叠。多元回归分析显示,他汀类药物和血管紧张素II 1型受体阻滞剂(ARB)治疗可抑制TAA中p22phox的表达。
我们的研究结果表明基于p22phox的NADH/NADPH氧化酶和局部肾素-血管紧张素系统在TAA发病机制中的作用。他汀类药物和ARB可能通过抑制NADH/NADPH氧化酶对动脉瘤的形成具有抑制作用。